Effect of an implant containing the GnRH agonist deslorelin on secretion of LH, ovarian activity and milk yield of postpartum dairy cows.
Prevention of high plasma progesterone concentrations in the early postpartum period may improve fertility. Our objective was to determine whether a Deslorelin implant (DESL; 2100 microg, s.c.) would reduce secretion of LH and alter follicle dynamics, plasma concentrations of progesterone, estradiol and PGF2alpha metabolite (PGFM) in postpartum dairy cows. Cows received DESL on Day 7 postpartum (Day 7, n=8) or were untreated (Control, n=9). All cows were injected with GnRH (100 microg, i.m.) on Day 14 to assess LH response. A protocol for synchronization of ovulation with timed AI was initiated on Day 60 (GnRH [Day 60], CIDR [Day 60 to Day 67], PGF2alpha [Day 67, 25 mg and Day 68, 15 mg], GnRH [Day 69] , AI [Day 70]). The LH response to injection of GnRH on Day 14 was blocked in animals treated with DESL. Numbers of Class 1 (<6 mm) follicles were unaffected (P > 0.05) whereas numbers of Class 2 (6 to 9 mm) (P < 0.01) and Class 3 (>9 mm) follicles were less (P < 0.01) in DESL cows between Day 7 and Day 21. From Day 22 to Day 60, DESL-treated cows had more of Class 1 follicles and less Class 2 (P < 0.01) and Class 3 (P < 0.01) follicles, and lower plasma concentrations of progesterone and estradiol (P < 0.01). Concentrations of PGFM between Day 7 and Day 42 were not affected by treatment (P > 0.05). All cows ovulated in response to GnRH on Day 69. Subsequent luteal phase increases in plasma progesterone concentrations (Day 70 to Day 84) did not differ. The use of the DESL implant associated with PGF2alpha given 14 days later suppressed ovarian activity and caused plasma progesterone concentrations to remain < 1 ng/mL between Day 22 and Day 51. The DESL implant did not affect milk production.
Mattos
R
R
Department of Animal Sciences, University of Florida, Gainesville, USA.
Orlandi
C
C
Williams
J
J
Staples
C R
CR
Trigg
T
T
Thatcher
W W
WW
D000818:Animals; D002417:Cattle / Q000502:physiology*; D015237:Dinoprost / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000097:blood; D004343:Drug Implants; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D004958:Estradiol / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology*; D007315:Insemination, Artificial / Q000662:veterinary; D007774:Lactation / Q000187:drug effects; D016014:Linear Models; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism*; D008297:Male; D008892:Milk / Q000378:metabolism*; D010053:Ovary / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism; D010060:Ovulation / Q000187:drug effects; D049590:Postpartum Period; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011897:Random Allocation; D017329:Triptorelin Pamoate / Q000031:analogs & derivatives; D014463:Ultrasonography
D004343:Drug Implants; D004791:Enzyme Inhibitors; D017329:Triptorelin Pamoate; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D015237:Dinoprost; C066438:deslorelin